• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

prostate cancer - Articles and news items

prostate cancer

Panacea initiates Phase I prostate cancer vaccine therapy trial

Industry news / 19 January 2017 / Niamh Marriott, Digital Editor

Panacea Pharmaceuticals have enrolled and dosed the first patient in the open-label, parallel designed, multi-centre Phase I clinical trial of PAN-301-1, for the treatment of persistent prostate cancer to assess safety and immunogenicity. Clinical sites for the PAN-301-1 trial are located in Alabama, California, Nebraska and South Carolina and the trial is managed by Accelovance. […]

NICE says ‘yes’ to degarelix for men with prostate cancer and spinal metastases

Industry news / 1 July 2016 / Victoria White, Digital Content Producer

NICE has recommended Ferring’s Firmagon (degarelix) for men with advanced-hormone dependent prostate cancer and spinal metastases…

Takeda and Roivant launch Myovant Sciences Ltd

Industry news / 7 June 2016 / Victoria White, Digital Content Producer

Myovant Sciences is a biopharmaceutical company focused on delivering innovative women’s health and prostate cancer therapeutics…

Bayer and Orion expand BAY-1841788 programme in prostate cancer

Industry news / 3 June 2016 / Victoria White, Digital Content Producer

The Phase III study ARASENS will evaluate BAY-1841788 in men with newly diagnosed metastatic hormone-sensitive prostate cancer…

NICE recommends Jevtana for advanced prostate cancer

Industry news / 25 May 2016 / Victoria White, Digital Content Producer

Jevtana has been recommended in combination with other drugs as a treatment option for metastatic hormone-relapsed prostate cancer in England…

NICE U-turn on cabazitaxel for prostate cancer

Industry news / 22 April 2016 / Victoria White, Digital Content Producer

NICE has issued final guidance recommending Sanofi’s Jevtana (cabazitaxel) for some prostate cancer patients…

Janssen and Tesaro in niraparib collaboration and license agreement

Industry news / 8 April 2016 / Victoria White, Digital Content Producer

Tesaro will receive an upfront payment of $35 million, and is eligible to receive additional milestone payments of up to $415 million…

 

Webinar: NIR Spectroscopy for Assessing Blend Uniformity in the Pharmaceutical IndustryLEARN MORE
+ +